Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Total revenues	$ 8,034,000	$ 1,169,000
Operating expenses (income):
Research and development	7,960,000	7,098,000
Gain on sale of Verdeca	(8,814,000)
Change in fair value of contingent consideration		(1,000,000)
Selling, general and administrative	16,467,000	13,567,000
Total operating expenses	20,812,000	20,550,000
Loss from operations	(12,778,000)	(19,381,000)
Interest expense	(47,000)	(5,000)
Other income, net	740,000	466,000
Change in fair value of common stock warrant liabilities	6,570,000	(9,243,000)
Loss on extinguishment of warrant liability	(635,000)
Offering costs		(708,000)
Net loss before income taxes	(6,150,000)	(28,871,000)
Income tax benefit (provision)	124,000	(2,000)
Net loss	(6,026,000)	(28,873,000)
Net loss attributable to non-controlling interest	(1,371,000)	(68,000)
Net loss attributable to common stockholders	$ (4,655,000)	$ (28,805,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.47)	$ (4.53)
Weighted-average number of shares used in per share calculations:
Basic and diluted	9,959,018	6,363,112
Other comprehensive (loss) income, net of tax
Unrealized (losses) gains on investment securities	$ (1,000)	$ 1,000
Other comprehensive (loss) income	(1,000)	1,000
Comprehensive loss attributable to common stockholders	(4,656,000)	(28,804,000)
Product
Revenues:
Total revenues	1,044,000	814,000
Operating expenses (income):
Cost of product revenues	5,199,000	885,000
License
Revenues:
Total revenues	6,801,000	67,000
Royalty
Revenues:
Total revenues	83,000
Contract Research And Government Grants
Revenues:
Total revenues	$ 106,000	$ 288,000